EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy

Kun Xiao, Xiaodan Qiu, Limin Zuo, Zhiling Zhu, Yiran Li, Yechun Zhang, Biao Li, Guangzhi Shan

Pharmaceutics · 20.11.2026 · 18 (11) · 1496

DOI: 10.3390/pharmaceutics18111496 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.11.2026. Verfasst von Kun Xiao und 7 weiteren Autor:innen. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Initiative for Innovative Medicine.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, poly(ADP-ribose) glycohydrolase (PARG), a key enzyme in DNA damage repair pathways, has emerged as a major focus in anticancer drug discovery. PARG inhibitors exhibit broad-spectrum antitumor effects across diverse tumor types via multiple mechanisms, such as triggering sustained nuclear replication stress and mitotic catastrophe, as well as modulating the stability of cell cycle checkpoint proteins. This review systematically summarizes the mechanisms of action of PARG inhibitors, recent advances in their structural optimization, and their applications in combination with immunotherapy, ATR/CHK1 inhibitors, and natural products, aiming to highlight the unique value and clinical translation prospects of PARG inhibitors as a new generation of highly selective, multi-mechanism antitumor agents.

Förderung

  • CAMS Initiative for Innovative Medicine

Zitieren

APA

Xiao, K., Qiu, X., Zuo, L., Zhu, Z., Li, Y., Zhang, Y., Li, B., & Shan, G. (2026). Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy. Pharmaceutics, 18(11), 1496. https://doi.org/10.3390/pharmaceutics18111496

Vancouver

Xiao K, Qiu X, Zuo L, Zhu Z, Li Y, Zhang Y, et al. Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy. Pharmaceutics. 2026;18(11):1496. doi:10.3390/pharmaceutics18111496

BibTeX
@article{Xiao2026,
  author = {Xiao, Kun and Qiu, Xiaodan and Zuo, Limin and Zhu, Zhiling and Li, Yiran and Zhang, Yechun and Li, Biao and Shan, Guangzhi},
  title = {Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1496},
  doi = {10.3390/pharmaceutics18111496}
}
Kostenlos starten →